Oral Beats Needles: Why QNТM’s Formulation Choice Matters

QNТМ will run Phase 2 with an oral Lucid-MS product made by a top CDMO. For MS trials, oral dosing improves adherence, lowers site complexity and reduces discontinuations vs injectables. That can sharpen your efficacy read across PET-MRI biomarkers. Add CSR-proven safety, IND prep underway, and a micro float, and you get a higher probability of a clean interim signal. Price reclaimed 25.40 and is angling for 26.

If momentum carries through 28.00, models start moving toward 35.26. The market often misprices boring operational wins. This one is not boring.